Bioenvision Names New Member to Board of Directors
October 10 2006 - 10:00AM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) a developer of oncology drugs
today announced Joseph P. Cooper has joined its board of directors
effective immediately. Mr. Cooper currently serves as Executive
Vice President, Corporate and Product Development at Medicis
Pharmaceutical Corporation (NYSE:MRX). Mr. Cooper has served at
Medicis for the past decade. He was named Executive Vice President,
Corporate and Product Development in July of this year. From
January 2001 to July 2006, Mr. Cooper served as Executive Vice
President, Corporate Development. From February 1996 to January
2001, he served as Senior Vice President, Manufacturing and
Distribution. Prior to that Mr. Cooper held management positions
with Schein Pharmaceuticals, Inc. and G.D. Searle. �We are
delighted to add someone of Joe�s prominence and commercial and
strategic expertise at this critical stage of Bioenvision�s
development,� said Dr. Christopher B. Wood, Chairman and Chief
Executive Officer of Bioenvision, Inc. �Joe has a proven track
record in the health care industry and we look forward to his
valuable insight and contributions as we expand our infrastructure
and the market for our drugs.� Mr. Cooper currently serves on the
Southwest Autism Research and Resource Center Board of Directors
and the University of Arizona Medical School Greater Phoenix
Leadership Board. About Bioenvision Bioenvision's primary focus is
the acquisition, development, distribution and marketing of
compounds and technologies for the treatment of cancer. Bioenvision
has a broad pipeline of products for the treatment of cancer,
including: Evoltra�, Modrenal� (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products. Bioenvision is also
developing anti-infective technologies, including the OLIGON�
technology, an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus�, an antimicrobial
agent currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our Web site at www.bioenvision.com. Certain statements
contained herein are "forward-looking" statements (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could
cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to
prove safe and effective for treatment of disease; uncertainties
inherent in the early stage of Bioenvision's compounds under
development; failure to successfully implement or complete clinical
trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that
change Bioenvision's business, structure or projections; the
development of competing products; uncertainties related to
Bioenvision's dependence on third parties and partners; and those
risks described in Bioenvision's filings with the SEC. Bioenvision
disclaims any obligation to update these forward-looking
statements. Bioenvision, Inc. (NasdaqGM:BIVN) a developer of
oncology drugs today announced Joseph P. Cooper has joined its
board of directors effective immediately. Mr. Cooper currently
serves as Executive Vice President, Corporate and Product
Development at Medicis Pharmaceutical Corporation (NYSE:MRX). Mr.
Cooper has served at Medicis for the past decade. He was named
Executive Vice President, Corporate and Product Development in July
of this year. From January 2001 to July 2006, Mr. Cooper served as
Executive Vice President, Corporate Development. From February 1996
to January 2001, he served as Senior Vice President, Manufacturing
and Distribution. Prior to that Mr. Cooper held management
positions with Schein Pharmaceuticals, Inc. and G.D. Searle. "We
are delighted to add someone of Joe's prominence and commercial and
strategic expertise at this critical stage of Bioenvision's
development," said Dr. Christopher B. Wood, Chairman and Chief
Executive Officer of Bioenvision, Inc. "Joe has a proven track
record in the health care industry and we look forward to his
valuable insight and contributions as we expand our infrastructure
and the market for our drugs." Mr. Cooper currently serves on the
Southwest Autism Research and Resource Center Board of Directors
and the University of Arizona Medical School Greater Phoenix
Leadership Board. About Bioenvision Bioenvision's primary focus is
the acquisition, development, distribution and marketing of
compounds and technologies for the treatment of cancer. Bioenvision
has a broad pipeline of products for the treatment of cancer,
including: Evoltra(R), Modrenal(R) (for which Bioenvision has
obtained regulatory approval for marketing in the United Kingdom
for the treatment of post-menopausal breast cancer following
relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies,
including the OLIGON(R) technology, an advanced biomaterial that
has been incorporated into various FDA approved medical devices and
Suvus(R), an antimicrobial agent currently in clinical development
for refractory chronic hepatitis C infection. For more information
on Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024